Topic: physician payments
Researchers scoured the database where pharma companies disclose payments made to physicians and discovered a troubling trend.
Transparency hasn't made much of a difference when it comes to drug and device makers' payments to doctors, which amounted to $2.6 billion last year.
In Germany, a nonprofit is trying disclosure based on the honor system.
California lawmakers are weighing a bill that would cut off most drugmaker payments to physicians, including speaking fees for that staple of pharma marketing, the slideshow over dinner.
If a proposed change in the way Medicare pays for injected drugs that doctors give at their offices goes forward, some companies will be hit harder than others. And according to a new report, one drugmaker in particular is at risk: Regeneron. And that is because of its strength in the marketplace, Eylea.
Another year of Sunshine Act data means another year's worth of dollar figures showing industry watchers just which drug brands are shelling out the most on payments to doctors.
The sun is finally shining on drug company payments to doctors in Europe, and payment information has begun to trickle out.
Drug and device makers handed over almost $6.5 billion to doctors and medical institutions in 2015, according to the latest Open Payments data, adding more stats for the debate over pharma's relationships with doctors.
JAMA lit a fuse in pharma last week with a study associating free meals for doctors with increases in branded prescriptions. Here's one marketing expert's take on that controversial conclusion.
A new JAMA study offers more evidence that doctors who collect more pharma payments prescribe more branded meds. Now, it's statin scripts at center: The higher the dollar amount, the higher the rate of brand scripts, rather than cheap generics.